- Molecular NameLisinopril
- SynonymNA
- Weight405.495
- Drugbank_IDDB00722
- ACS_NO76547-98-3
- Show 3D model
- LogP (experiment)-1.22
- LogP (predicted, AB/LogP v2.0)-1.37
- pka2.5, 4.0, 6.7, 10.1
- LogD (pH=7, predicted)-1.97
- Solubility (experiment)97 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.18
- LogSw (predicted, AB/LogsW2.0)30.76
- Sw (mg/ml) (predicted, ACD/Labs)12.38
- No.of HBond Donors5
- No.of HBond Acceptors8
- No.of Rotatable Bonds12
- TPSA132.96
- StatusFDA approved
- AdministrationPO
- PharmacologyA drug of the angiotensin converting enzyme (ACE) inhibitor class that is primarily used in treatment of hypertension, congestive heart failure, heart attacks and also in preventing renal and retinal complications of diabetes.
- Absorption_value27.0
- Absorption (description)Lisinopril is slowly and incompletely absorbed after oral administration. Absorption varies between 6 and 60% depending on the individual, but on average is 25% of the dose.
- Caco_2N/A
- Bioavailability25.0
- Protein binding0.0
- Volume of distribution (VD)2.4 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmMetabolism does not occur as it is already an active diacid (a lysine derivative of enalaprilat).
- Half life12 h
- ExcretionThe absorbed drug is excreted unchanged in urine via the kidneys and the unabsorbed drug is excreted in faeces.
- Urinary ExcretionN/A
- Clerance4.2 ml/min/kg
- ToxicityN/A
- LD50 (rat)LD50= 2000 mg/kg
- LD50 (mouse)N/A